Belinostat (PXD101)

Synonym(s):(2E)-N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide;(2E)-N-Hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-2-propenamide;(E)-N-Hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide;

CAS NO.：414864-00-9
Empirical Formula: C15H14N2O4S
Molecular Weight: 318.35
MDL number: MFCD08064035
SAFETY DATA SHEET (SDS)
Update Date: 2023-05-18 11:31:10

What is Belinostat (PXD101)?

Description

Belinostat is a drug which was developed by Spectrum Pharmaceuticals and is currently marketed by Onxeo as Beleodaq®. The drug, which received fast track designation by the United States Food and Drug Administration (US FDA) and was approved for the treatment of hematological malignancies and solid tumors associated with peripheral T-cell lymphoma (PTCL) in 2014, is a histone deacetylase (HDAC) inhibitor and is the third such treatment to receive accelerated approval for PTCL, the others being vorinostat (Zolinza®) and pralatrexate (Folotyn®). Although belinostat was not yet approved in Europe as of August 2014, the compound exhibits a safety profile considered to be acceptable for HDAC inhibitors–less than 25% of patients reported adverse effects and these most frequently were nausea, fatigue, pyrexia, anemia, and emesis.

The Uses of Belinostat (PXD101)

Belinostat is a novel histone deacetylase 3 selective inhibitor, which protects the β cells from cytokine-induced apoptosis.

What are the applications of Application

Belinostat is a novel HDAC inhibitor

Properties of Belinostat (PXD101)

Melting point:	142 - 145°C
Density	1.427±0.06 g/cm3(Predicted)
storage temp.	Amber Vial, Refrigerator, Under inert atmosphere
solubility	DMSO (Slightly), Methanol (Slightly)
form	Solid
color	Off-White to Pale Orange